22 completed, 6 recruiting, 4 not yet recruiting, 2 unknown. 11 Phase 1, 10 Phase 2, 10 Phase 3, 3 Not applicable, 2 Phase 4.
Follow Xiamen Amoytop Biotech Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) ACT500 tablets - Metabolic Dysfunction-associated Steatohepatitis | Phase 1 | Not yet recruiting | Xiamen Amoytop Biotech Co., Ltd. | 24 | 2026-10-31 | 2026-09-14 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B ACT500 Tablets, ACT500 Placebo Tablets - Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b | Phase 1 | Not yet recruiting | Xiamen Amoytop Biotech Co., Ltd. | 24 | 2026-10-30 | 2026-09-14 |
| ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis B (CHB) ACT201 Injection, ACT201 Injection Placebo - Chronic Hepaititis B | Phase 1 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 72 | 2026-08-06 | 2026-08-17 |
| The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature Inpegsomatropin-Injection, Givopegsomatropin Solution Injection - Turner Syndrome | Phase 3 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 84 | 2026-07-05 | 2026-07-22 |
| Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency Inpegsomatropin Injection, Placebo for Inpegsomatropin Injection - Adult Growth Hormone Deficiency | Phase 2 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 36 | 2026-06-10 | 2026-07-22 |
| Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants.. ACT100 Injection, Placebo for ACT100 - Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 1 | Not yet recruiting | Xiamen Amoytop Biotech Co., Ltd. | 48 | 2026-03-06 | 2026-02-13 |
| Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia Topefilgrastim Injection - Preeclampsia | Not applicable | Not yet recruiting | Fang Wang | 100 | 2026-01-31 | 2026-02-03 |
| The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age Inpegsomatropin Injection, Recombinant Human Growth Hormone Injection - Small for Gestational Age | Phase 3 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 141 | 2026-01-20 | 2026-05-08 |
| The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature Inpegsomatropin Injection, Recombinant Human Growth Hormone Injection - Idiopathic Short Stature | Phase 3 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 300 | 2025-04-28 | 2026-03-11 |
| Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing Telpegfilgrastim Injection - Preeclampsia | Phase 1 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 18 | 2025-04-06 | 2026-04-13 |
| Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females Telpegfilgrastim Injection - Preeclampsia | Phase 1 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 18 | 2025-03-26 | 2025-05-30 |
| Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants ACT500 tablets, Placebo - Non-alcoholic Steatohepatitis | Phase 1 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 72 | 2025-03-06 | 2026-02-17 |
| Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET Peginterferon α-2b injection - Essential Thrombocythemia | Phase 2 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 27 | 2024-08-29 | 2025-11-17 |
| A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate - Chronic Hepatitis B | Not applicable | Enrolling by invitation | Xiamen Amoytop Biotech Co., Ltd. | 350 | 2022-03-18 | 2024-12-04 |
| A Trial of YPEG-rhGH in Children With Short Stature YPEG-rhGH, rhGH - Idiopathic Short Stature, Small for Gestational Age | Phase 2 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 78 | 2022-02-15 | 2024-01-24 |
| A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease YPEG-rhEPO - Renal Anemia of Chronic Kidney Disease | Phase 2 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 60 | 2021-03-12 | 2022-12-16 |
| Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy YPEG-rhG-CSF, rhG-CSF/PEG-rhG-CSF - Non-Myeloid Malignancy | Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 398 | 2020-10-16 | 2022-02-09 |
| A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B Peginterferon alfa-2b injection, TDF - Chronic Hepatitis B | Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 475 | 2019-12-04 | 2024-03-05 |
| Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children Y-shape pegylated somatropin, Norditropin®, Norditropin - Growth Hormone Deficiency | Phase 2 / Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 434 | 2018-12-26 | 2024-01-24 |
| Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy PegIFN α- 2b - Chronic Hepatitis B | Not applicable | Completed | Henan Provincial People's Hospital | 33 | 2017-12-01 | 2022-07-13 |
Showing 20 of 35. Sign in to see all of them.
Hepatitis B, Chronic (8) · Pre-Eclampsia (3) · Dwarfism, Pituitary (2) · Febrile Neutropenia (2) · Hepatitis B (2) · Hepatitis C, Chronic (2) · Neutropenia (2) · Turner Syndrome (2) · Anemia (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Dwarfism (1) · Hepadnaviridae Infections (1) · Hepatitis C (1) · Hepatitis, Chronic (1)
peginterferon alfa-2a (6) · peginterferon alfa-2b (5) · Colony-Stimulating Factors (2) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Growth Hormone (2) · pegylated granulocyte colony-stimulating factor (2) · Granulocyte Colony-Stimulating Factor (1) · Human Growth Hormone (1) · Interleukin-11 (1) · Long-Term Synaptic Depression (1) · adefovir dipivoxil (1) · entecavir (1) · oprelvekin (1)
China (33) · Egypt (1)
Guiqiang Wang, Ph.D (2) · Wei Lai, MD, PhD (2) · Wei Zhenman, Ph.D (2) · Xiaoping Luo, Ph.D (2) · Chun Wang, M.D. (1) · Dongyang Liu, Ph.D (1) · Fang Wang (1) · Gamal Esmat, MD (1) · Guiqiang Wang, MD (1) · Hu Pei, Ph.D (1) · Jia Shang (1) · JianYing Huang (1) · Jidong Jia, Ph.D (1) · Jing Zhang, Ph.D. (1) · Lai Wei (1)
PMID 24625322, PMID 26392095, PMID 35149125, PMID 36034448, PMID 37577817, PMID 40098083, PMID 40665748, PMID 41051280, PMID 41366186